Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma

Br J Haematol. 2014 Mar;164(5):750-2. doi: 10.1111/bjh.12678.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Dexamethasone / therapeutic use*
  • Drug Therapy, Combination / methods
  • Female
  • Humans
  • Immunoblastic Lymphadenopathy / drug therapy
  • Lenalidomide
  • Lymphoma, T-Cell / drug therapy*
  • Pyrazines / therapeutic use*
  • Salvage Therapy / methods*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Tomography, Emission-Computed

Substances

  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Lenalidomide